Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)
- 1 June 2012
- journal article
- research article
- Published by Springer Nature in BioDrugs
- Vol. 26 (3) , 177-184
Abstract
Objective: HD203 is a biosimilar of etanercept, a fusion protein of the ligand-binding portion of the human tumor necrosis factor receptor II linked to the Fc portion of human immunoglobulin G1. Since HD203 is under clinical development, this study was conducted to compare the pharmacokinetics of HD203 with Enbrel ®, the first marketed etanercept. Methods: A double-blind, randomized, single-dose, two-period, two-sequence, crossover study was conducted in 37 healthy volunteers. In each period, 25mg/mL of reconstituted lyophilized reference (Enbrel®) or test product (HD203) was administered subcutaneously, either the reference product followed by the test product, or vice versa. Serial blood samples for pharmacokinetic analysis were taken for 480 hours after dosing, and serum concentrations of the products were determined using a commercial enzyme-linked immunosorbent assay. The geometric mean ratios with 90% confidence intervals for the maximum concentration (Cmax) and the area under the concentration-time curve from time 0 to the last measurable time point (AUC0-t) were estimated. Results: A total of 35 subjects completed the study; serious adverse events were not observed. The mean serum concentration-time profiles of the two products were similar. The Cmax and AUC0-t values of the reference product (mean±standard deviation) were 1.25±0.45mg/L and 283.15 ± 98.57mg*h/L, respectively, while those of the test drug were 1.35 ± 0.47 mg/L and 315.78±99.38 mg*h/L, respectively. The geometric mean ratios (90% confidence intervals) of the test to the reference for Cmax and AUC0-t were 1.08 (1.00, 1.16) and 1.13 (1.05, 1.21), respectively. Conclusions: A single subcutaneous injection of HD203 or Enbrel ® into healthy volunteers appeared to be safe and well tolerated. Comparative pharmacokinetics demonstrated that reconstituted lyophilized HD203 has bioavailability similar to that of Enbrel®.Keywords
This publication has 15 references indexed in Scilit:
- Evaluation of Process Efficiency and Bioequivalence of Biosimilar Recombinant Human Chorionic Gonadotropin (rhCG)BioDrugs, 2011
- Biosimilars: a regulatory perspective from AmericaArthritis Research & Therapy, 2011
- Bioequivalence Studies of Omnitrope, the First Biosimilar/rhGH Follow‐on Protein: Two Comparative Phase 1 Randomized Studies and Population Pharmacokinetic AnalysisThe Journal of Clinical Pharmacology, 2010
- Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®BioDrugs, 2009
- Bioequivalence of Liquid and Reconstituted Lyophilized Etanercept Subcutaneous InjectionsThe Journal of Clinical Pharmacology, 2006
- Mechanisms of differential immunogenicity of tumor necrosis factor inhibitorsCurrent Rheumatology Reports, 2005
- Absence of a Clinically Relevant Interaction Between Etanercept and DigoxinThe Journal of Clinical Pharmacology, 2004
- Etanercept: An overviewJournal of the American Academy of Dermatology, 2003
- OPEN QUESTIONS ON BIOEQUIVALENCE: SOME PROBLEMS AND SOME SOLUTIONSPharmacological Research, 1999
- Influence of height, weight and obesity on risk of breast cancer in an unselected Swedish populationBritish Journal of Cancer, 1977